PATENT CLAIM ANALYSIS

Application Number: 16301826
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-06
Patent Classification: ["514", "254060"]

Abstract:
The present invention relates to a new crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, process for its preparation, its utility in treating diseases caused by deregulated protein kinase activity and pharmaceutical compositions containing it.

Claim (Index 21):
The crystalline Form 4 according to  claim 20 , wherein said X-ray powder diffraction pattern further comprises the significant peaks at a reflection angle 2-theta of about 10.3, 11.0, 11.9, 14.3, 14.6, 15.1, 15.3, 16.1, 17.1, 19.0, 19.2, 19.6, 19.7, 20.1, 20.7, 21.3, 22.1, 22.7, 24.3, 24.6, 25.3, 25.5, 25.9, 26.7, 26.9, 27.3, 27.7, 28.1, 28.6, 29.0, 29.5, 29.9, 30.5, 31.0, 31.6, 32.2, 33.3, 34.0, 35.4, 36.4 and 36.8\u00b10.2 degrees.

Metadata:
- Claim Count in Document: 35.0
- Percentile: 98.0
- Lexical Diversity: 1.13636
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14623904', '16050516', '16051815', '14953969', '15172478']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7732717407015981
- 35 USC 102 Novelty (BERT): 0.5192988399114334
- Combined Prediction Score: 0.7478744506225816
- Mean Citation Score: 293.132042
- Max Citation Score: 305.8803
- Similarity Product: 213.3295551414013

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test